Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
decreases	O
,	O
and	O
interleukin-10	B-protein
increases	O
,	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
to	O
dexamethasone	O
:	O
potential	O
regulation	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
.	O

Resistance	O
to	O
glucocorticoid	O
therapy	O
has	O
been	O
observed	O
in	O
patients	O
with	O
autoimmune/inflammatory	O
diseases	O
and	O
may	O
be	O
related	O
to	O
the	O
inflammatory	O
process	O
itself	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
ability	O
of	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNFalpha	B-protein
,	O
a	O
proinflammatory	B-protein
cytokine	I-protein
)	O
and	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-10	I-protein
(	O
an	O
anti-inflammatory	B-protein
cytokine	I-protein
)	O
to	O
differentially	O
regulate	O
the	O
sensitivity	O
of	O
human	B-cell_type
monocytes	I-cell_type
/macrophages	B-cell_type
to	O
glucocorticoids	O
.	O

To	O
accomplish	O
this	O
,	O
we	O
first	O
analyzed	O
the	O
pattern	O
of	O
TNFalpha	B-protein
and	O
IL-10	O
inhibition	O
by	O
dexamethasone	O
in	O
LPS-stimulated	B-cell_line
whole-blood	I-cell_line
cell	I-cell_line
cultures	I-cell_line
.	O

Second	O
,	O
we	O
studied	O
the	O
modulation	O
of	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
dexamethasone	O
by	O
preincubation	O
with	O
TNFalpha	B-protein
or	O
IL-10	B-protein
and	O
measurement	O
of	O
LPS-stimulated	O
IL-6	B-protein
secretion	O
.	O

In	O
addition	O
,	O
we	O
evaluated	O
the	O
effect	O
of	O
dexamethasone	O
on	O
phorbolmyristate-acetate-stimulated	O
IL-1	B-protein
receptor	I-protein
antagonist	O
secretion	O
by	O
the	O
human	B-cell_line
monocytic	I-cell_line
cell	I-cell_line
line	I-cell_line
U937	I-cell_line
.	O

Finally	O
,	O
we	O
investigated	O
whether	O
the	O
modulation	O
of	O
corticosensitivity	O
in	O
TNFalpha-	B-cell_line
and	I-cell_line
IL-10-pretreated	I-cell_line
U937	I-cell_line
cells	I-cell_line
was	O
related	O
to	O
a	O
change	O
of	O
the	O
glucocorticoid	B-protein
receptor	I-protein
concentration	O
and	O
affinity	O
.	O

Dexamethasone	O
had	O
different	O
effects	O
on	O
LPS-induced	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
;	O
whereas	O
it	O
suppressed	O
TNFalpha	B-protein
in	O
a	O
dose-dependent	O
fashion	O
,	O
its	O
effect	O
on	O
IL-10	B-protein
secretion	O
was	O
biphasic	O
,	O
producing	O
stimulation	O
at	O
lower	O
,	O
and	O
inhibition	O
at	O
higher	O
doses	O
.	O

The	O
concentration	O
of	O
LPS	O
employed	O
influenced	O
the	O
effect	O
of	O
dexamethasone	O
on	O
IL-10	B-protein
secretion	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Pretreatment	O
with	O
TNFalpha	B-protein
diminished	O
,	O
and	O
with	O
IL-10	B-protein
improved	O
,	O
the	O
ability	O
of	O
dexamethasone	O
to	O
suppress	O
IL-6	B-protein
secretion	O
in	O
whole-blood	B-cell_type
cell	I-cell_type
cultures	I-cell_type
(	O
P	O
<	O
0.01	O
for	O
both	O
)	O
and	O
to	O
enhance	O
IL-1	B-protein
receptor	O
antagonist	O
secretion	O
by	O
U937	O
cells	O
(	O
P	O
<	O
0.05	O
for	O
both	O
)	O
.	O

TNFalpha	B-protein
decreased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
while	O
IL-10	B-protein
increased	O
(	O
P	O
<	O
0.001	O
)	O
,	O
the	O
concentration	O
of	O
dexamethasone	O
binding	O
sites	O
in	O
these	O
cells	O
,	O
with	O
no	O
discernible	O
effect	O
on	O
their	O
binding	O
affinity	O
.	O

We	O
conclude	O
that	O
glucocorticoids	O
differentially	O
modulate	O
TNFalpha	B-protein
and	O
IL-10	B-protein
secretion	O
by	O
human	B-cell_type
monocytes	I-cell_type
in	O
a	O
LPS	O
dose-dependent	O
fashion	O
and	O
that	O
the	O
sensitivity	O
of	O
these	O
cells	O
to	O
glucocorticoids	O
is	O
altered	O
by	O
TNFalpha	B-protein
or	O
IL-10	B-protein
pretreatment	O
;	O
TNFalpha	B-protein
blocks	O
their	O
effects	O
,	O
whereas	O
IL-10	B-protein
acts	O
synergistically	O
with	O
glucocorticoids	O
.	O

This	O
is	O
accompanied	O
by	O
opposite	O
glucocorticoid	B-protein
receptor	I-protein
changes	O
,	O
respectively	O
opposing	O
and	O
favoring	O
glucocorticoid	O
actions	O
.	O

This	O
study	O
suggests	O
that	O
the	O
pattern	O
of	O
pro-/antiinflammatory	O
cytokine	B-protein
secretion	O
may	O
alter	O
the	O
response	O
of	O
patients	O
to	O
glucocorticoid	O
therapy	O
.	O

0021-972	NULL
%	NULL
/99/	NULL
$	NULL
03.00/0	NULL
The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Endocrinology	NULL
&	NULL
Metabolism	NULL
Copyright	NULL
©	NULL
1999	NULL
by	NULL
The	NULL
Endocrine	NULL
Society	NULL
Vol	NULL
.	NULL

84	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Tumor	NULL
Necrosis	NULL
Factor	NULL
a	NULL
Decreases	NULL
,	NULL
and	NULL
Interleukin-10	NULL
Increases	NULL
,	NULL
the	NULL
Sensitivity	NULL
of	NULL
Human	NULL
Monocytes	NULL
to	NULL
Dexamethasone	NULL
:	NULL
Potential	NULL
Regulation	NULL
of	NULL
the	NULL
Glucocorticoid	NULL
Receptor	NULL
DENIS	NULL
FRANCHIMONT*	NULL
,	NULL
HENRI	NULL
MARTENS	NULL
,	NULL
MARIE-THERESE	NULL
HAGELSTEIN	NULL
,	NULL
EDOUARD	NULL
LOUIS	NULL
,	NULL
WALTHERE	NULL
DEWE	NULL
,	NULL
GEORGE	NULL
P.	NULL
CHROUSOS	NULL
,	NULL
JACQUES	NULL
BELAICHE	NULL
,	NULL
anp	NULL
VINCENT	NULL
GEENEN	NULL
Laboratory	NULL
of	NULL
Radio-Immunology	NULL
and	NULL
Neurcendocrine-Immunology	NULL
(	NULL
D.F	NULL
.	NULL

,	NULL
HM	NULL
.	NULL

,	NULL
M.-T.H	NULL
.	NULL

,	NULL
W.D	NULL
.	NULL

,	NULL
V.G	NULL
.	NULL
)	NULL

,	NULL
Institute	NULL
of	NULL
Pathology	NULL
,	NULL
Department	NULL
of	NULL
Gastroenterology	NULL
CHU	NULL
(	NULL
D.F	NULL
.	NULL

,	NULL
E.L.	NULL
,	NULL
J.B.	NULL
)	NULL
,	NULL
University	NULL
of	NULL
Liége	NULL
,	NULL
Belgium	NULL
;	NULL
and	NULL
Developmental	NULL
Endocrinology	NULL
Branch	NULL
(	NULL
D.F	NULL
.	NULL

,	NULL
G.P.C	NULL
.	NULL
)	NULL

,	NULL
NICHD	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
ABSTRACT	NULL
Resistance	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
has	NULL
been	NULL
observed	NULL
in	NULL
patients	NULL
with	NULL
autoimmune/inflammatory	NULL
diseases	NULL
and	NULL
may	NULL
be	NULL
related	NULL
to	NULL
the	NULL
inflammatory	NULL
process	NULL
itself	NULL
.	NULL

The	NULL
aim	NULL
of	NULL
this	NULL
study	NULL
was	NULL
to	NULL
examine	NULL
the	NULL
ability	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNFa	NULL
,	NULL
a	NULL
proinflammatory	NULL
cytokine	NULL
)	NULL
and	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-10	NULL
(	NULL
an	NULL
anti-inflammatory	NULL
cytokine	NULL
)	NULL
to	NULL
differentially	NULL
regulate	NULL
the	NULL
sensitivity	NULL
of	NULL
human	NULL
monocytes/macrophages	NULL
to	NULL
glucocorticoids	NULL
.	NULL

To	NULL
accomplish	NULL
this	NULL
,	NULL
we	NULL
first	NULL
analyzed	NULL
the	NULL
pattern	NULL
of	NULL
TNFa	NULL
and	NULL
IL-10	NULL
inhibition	NULL
by	NULL
dexamethasone	NULL
in	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
.	NULL

Second	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
modulation	NULL
of	NULL
the	NULL
sensitivity	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
dexamethasone	NULL
by	NULL
preincubation	NULL
with	NULL
TNFa	NULL
or	NULL
IL-10	NULL
and	NULL
measurement	NULL
of	NULL
LPS-stimulated	NULL
IL-6	NULL
secretion	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
we	NULL
evaluated	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
phorbol-myristate-acetate-stimulated	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
secretion	NULL
by	NULL
the	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
U9837	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
investigated	NULL
whether	NULL
the	NULL
modulation	NULL
of	NULL
corticosensitivity	NULL
in	NULL
TNFa	NULL
«	NULL
-	NULL
and	NULL
IL-10-pretreated	NULL
U937	NULL
cells	NULL
was	NULL
related	NULL
to	NULL
a	NULL
change	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
concentration	NULL
and	NULL
affinity	NULL
.	NULL

Dexamethasone	NULL
had	NULL
different	NULL
effects	NULL
on	NULL
LPS-induced	NULL
TNFa	NULL
and	NULL
IL-10	NULL
secretion	NULL
;	NULL
whereas	NULL
it	NULL
suppressed	NULL
TNFa	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
,	NULL
its	NULL
effect	NULL
on	NULL
IL-10	NULL
secretion	NULL
was	NULL
biphasic	NULL
,	NULL
producing	NULL
stimulation	NULL
at	NULL
lower	NULL
,	NULL
and	NULL
inhibition	NULL
at	NULL
higher	NULL
doses	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
LPS	NULL
employed	NULL
influenced	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
IL-10	NULL
secretion	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Pretreatment	NULL
with	NULL
TNFa	NULL
dimin-ished	NULL
,	NULL
and	NULL
with	NULL
IL-10	NULL
improved	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
dexamethasone	NULL
to	NULL
suppress	NULL
IL-6	NULL
secretion	NULL
in	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
for	NULL
both	NULL
)	NULL
and	NULL
to	NULL
enhance	NULL
IL-1	NULL
receptor	NULL
antagonist	NULL
secretion	NULL
by	NULL
U937	NULL
cells	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
for	NULL
both	NULL
)	NULL
.	NULL

TNFa	NULL
decreased	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
while	NULL
IL-10	NULL
increased	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
dexamethasone	NULL
binding	NULL
sites	NULL
in	NULL
these	NULL
cells	NULL
,	NULL
with	NULL
no	NULL
discernible	NULL
effect	NULL
on	NULL
their	NULL
binding	NULL
affinity	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
glucocorticoids	NULL
differentially	NULL
modulate	NULL
TNFa	NULL
and	NULL
IL-10	NULL
secretion	NULL
by	NULL
human	NULL
monocytes	NULL
in	NULL
a	NULL
LPS	NULL
dose-dependent	NULL
fashion	NULL
and	NULL
that	NULL
the	NULL
sensitivity	NULL
of	NULL
these	NULL
cells	NULL
to	NULL
glucocorticoids	NULL
is	NULL
altered	NULL
by	NULL
TNFa	NULL
or	NULL
IL-10	NULL
pretreatment	NULL
;	NULL
TNFa	NULL
blocks	NULL
their	NULL
effects	NULL
,	NULL
whereas	NULL
IL-10	NULL
acts	NULL
syner-gistically	NULL
with	NULL
glucocorticoids	NULL
.	NULL

This	NULL
is	NULL
accompanied	NULL
by	NULL
opposite	NULL
glucocorticoid	NULL
receptor	NULL
changes	NULL
,	NULL
respectively	NULL
opposing	NULL
and	NULL
favoring	NULL
glucocorticoid	NULL
actions	NULL
.	NULL

This	NULL
study	NULL
suggests	NULL
that	NULL
the	NULL
pattern	NULL
of	NULL
pro-/	NULL
antiinflammatory	NULL
cytokine	NULL
secretion	NULL
may	NULL
alter	NULL
the	NULL
response	NULL
of	NULL
patients	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
.	NULL

(	NULL
J	NULL
Clin	NULL
Endocrinol	NULL
Metab	NULL
84	NULL
:	NULL
2834-2839	NULL
,	NULL
1999	NULL
)	NULL
GLUCOCORTICOIDS	NULL
are	NULL
widely	NULL
employed	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
autoimmune	NULL
and	NULL
inflammatory	NULL
diseases	NULL
(	NULL
1	NULL
)	NULL
.	NULL

Varying	NULL
sensitivity	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
has	NULL
emerged	NULL
from	NULL
the	NULL
different	NULL
clinical	NULL
responses	NULL
to	NULL
glucocorticoids	NULL
among	NULL
the	NULL
multitude	NULL
of	NULL
patients	NULL
with	NULL
autoimmune/	NULL
inflammatory	NULL
diseases	NULL
,	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
which	NULL
they	NULL
are	NULL
classified	NULL
as	NULL
corticosteroid-sensitive	NULL
or	NULL
corticosteroid-resistant	NULL
.	NULL

The	NULL
response	NULL
of	NULL
the	NULL
disease	NULL
to	NULL
glucocorticoid	NULL
therapy	NULL
depends	NULL
not	NULL
only	NULL
on	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
(	NULL
GR	NULL
)	NULL
concentration	NULL
and	NULL
binding	NULL
affinity	NULL
but	NULL
also	NULL
on	NULL
postreceptor	NULL
mechanisms	NULL
and	NULL
interactions	NULL
of	NULL
the	NULL
GR	NULL
with	NULL
DNA	NULL
hormone-responsive	NULL
elements	NULL
and	NULL
other	NULL
nuclear	NULL
factors	NULL
,	NULL
such	NULL
as	NULL
AP-1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
.	NULL

The	NULL
glucocorticoid	NULL
resistance	NULL
observed	NULL
in	NULL
inflammatory	NULL
Received	NULL
October	NULL
21	NULL
,	NULL
1998	NULL
.	NULL

Revision	NULL
received	NULL
March	NULL
12	NULL
,	NULL
1999	NULL
.	NULL

Accepted	NULL
April	NULL
30	NULL
,	NULL
1999	NULL
.	NULL

Address	NULL
all	NULL
correspondence	NULL
and	NULL
requests	NULL
for	NULL
reprints	NULL
to	NULL
:	NULL
Denis	NULL
Franchimont	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Developmental	NULL
Endocrinology	NULL
Branch	NULL
,	NULL
NICHD	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
10N262	NULL
,	NULL
10	NULL
Center	NULL
Drive	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
.	NULL

*	NULL
Research	NULL
Assistant	NULL
of	NULL
the	NULL
Belgian	NULL
National	NULL
Foundation	NULL
for	NULL
Scientific	NULL
Research	NULL
and	NULL
supported	NULL
by	NULL
the	NULL
Leon	NULL
Fredericq	NULL
Foundation	NULL
.	NULL

diseases	NULL
may	NULL
be	NULL
induced	NULL
by	NULL
the	NULL
inflammatory	NULL
process	NULL
and/or	NULL
be	NULL
genetically	NULL
or	NULL
constitutionally	NULL
determined	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Cytokines	NULL
,	NULL
the	NULL
main	NULL
endocrine	NULL
,	NULL
paracrine	NULL
,	NULL
and	NULL
autocrine	NULL
factors	NULL
of	NULL
the	NULL
immune/inflammatory	NULL
response	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
modulate	NULL
the	NULL
sensitivity	NULL
of	NULL
immune	NULL
cells	NULL
to	NULL
glucocorticoids	NULL
(	NULL
6-10	NULL
)	NULL
.	NULL

Tumor	NULL
necrosis	NULL
factor	NULL
«	NULL
(	NULL
TNFa	NULL
,	NULL
a	NULL
proinflammatory	NULL
cytokine	NULL
)	NULL
and	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-10	NULL
(	NULL
a	NULL
T	NULL
helper	NULL
2-type	NULL
and	NULL
antiinflammatory	NULL
cytokine	NULL
)	NULL
are	NULL
secreted	NULL
by	NULL
activated	NULL
macrophages	NULL
and	NULL
play	NULL
opposite	NULL
roles	NULL
in	NULL
both	NULL
innate	NULL
and	NULL
specific	NULL
immune	NULL
responses	NULL
(	NULL
11-15	NULL
)	NULL
.	NULL

Monocytes/macrophages	NULL
,	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
,	NULL
are	NULL
of	NULL
major	NULL
importance	NULL
in	NULL
the	NULL
decision	NULL
for	NULL
differentiation	NULL
of	NULL
naive	NULL
Th0	NULL
CD4+	NULL
cells	NULL
toward	NULL
Th1-	NULL
directed	NULL
cellular	NULL
immunity	NULL
or	NULL
Th2-directed	NULL
humoral	NULL
immunity	NULL
.	NULL

Glucocorticoids	NULL
promote	NULL
a	NULL
shift	NULL
from	NULL
Th1-type	NULL
and	NULL
proinflammatory	NULL
to	NULL
Th2-type	NULL
and	NULL
antiinflammatory	NULL
cytokine	NULL
secretory	NULL
pattern	NULL
.	NULL

This	NULL
is	NULL
because	NULL
the	NULL
former	NULL
is	NULL
strongly	NULL
inhibited	NULL
by	NULL
glucocorticoids	NULL
,	NULL
whereas	NULL
the	NULL
latter	NULL
is	NULL
not	NULL
or	NULL
positively	NULL
affected	NULL
(	NULL
16-19	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
hypothesized	NULL
that	NULL
cytokines	NULL
could	NULL
differentially	NULL
regulate	NULL
the	NULL
sensitivity	NULL
of	NULL
normal	NULL
human	NULL
2834	NULL
GLUCOCORTICOID	NULL
,	NULL
TNFa	NULL
,	NULL
AND	NULL
IL-10	NULL
monocytes	NULL
/macrophages	NULL
from	NULL
healthy	NULL
subjects	NULL
to	NULL
glucocorticoids	NULL
in	NULL
a	NULL
fashion	NULL
that	NULL
could	NULL
be	NULL
influenced	NULL
by	NULL
the	NULL
balance	NULL
of	NULL
proinflammatory	NULL
/antiinflammatory	NULL
cytokine	NULL
secretion	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
first	NULL
analyzed	NULL
the	NULL
pattern	NULL
of	NULL
dexamethasone-mediated	NULL
inhibition	NULL
of	NULL
TNFa	NULL
and	NULL
IL-10	NULL
secretion	NULL
by	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
;	NULL
and	NULL
,	NULL
second	NULL
,	NULL
we	NULL
studied	NULL
the	NULL
modulation	NULL
of	NULL
the	NULL
dexamethasone	NULL
responses	NULL
of	NULL
human	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
or	NULL
of	NULL
a	NULL
phorbol-ester-stimulated	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
by	NULL
preincubation	NULL
with	NULL
TNFa	NULL
or	NULL
IL-10	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Whole-blood	NULL
cell	NULL
cultures	NULL
Ten	NULL
healthy	NULL
male	NULL
volunteers	NULL
(	NULL
age	NULL
range	NULL
,	NULL
25-45	NULL
yr	NULL
old	NULL
)	NULL
served	NULL
as	NULL
blood	NULL
donors	NULL
.	NULL

The	NULL
blood	NULL
was	NULL
treated	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

The	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
were	NULL
treated	NULL
as	NULL
follows	NULL
:	NULL
1	NULL
)	NULL
LPS	NULL
(	NULL
endotoxin	NULL
from	NULL
Salmonella	NULL
enteritidis	NULL
,	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
either	NULL
100	NULL
pg/mL	NULL
,	NULL
1	NULL
ng/mL	NULL
,	NULL
or	NULL
10	NULL
ng/mL..	NULL

In	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
,	NULL
the	NULL
mononuclear	NULL
cells	NULL
activated	NULL
by	NULL
LPS	NULL
are	NULL
mainly	NULL
monocytes	NULL
Dexamethasone	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
ranging	NULL
from	NULL
10	NULL
°-10~®	NULL
mol/L	NULL
in	NULL
separate	NULL
wells	NULL
containing	NULL
LPS	NULL
.	NULL

Plates	NULL
were	NULL
incubated	NULL
at	NULL
37	NULL
C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

The	NULL
incubation	NULL
periods	NULL
for	NULL
LPS-stimulated	NULL
whole	NULL
blood	NULL
were	NULL
24	NULL
h	NULL
and	NULL
48	NULL
h.	NULL
2	NULL
)	NULL
LPS	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
ng/mL	NULL
.	NULL

Twenty-four	NULL
hours	NULL
and	NULL
48	NULL
h	NULL
before	NULL
LPS	NULL
stimulation	NULL
,	NULL
the	NULL
whole-blood	NULL
cell	NULL
culture	NULL
was	NULL
incubated	NULL
alone	NULL
or	NULL
either	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TNFa	NULL
(	NULL
1	NULL
ng/mL	NULL
)	NULL
or	NULL
IL-10	NULL
(	NULL
50	NULL
pg/mL	NULL
)	NULL
.	NULL

Dexamethasone	NULL
was	NULL
added	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
®	NULL
mol/L	NULL
in	NULL
separate	NULL
wells	NULL
containing	NULL
LPS	NULL
.	NULL

Plates	NULL
were	NULL
incubated	NULL
at	NULL
37	NULL
C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

The	NULL
incubation	NULL
period	NULL
for	NULL
LPS-stimulated	NULL
whole	NULL
blood	NULL
was	NULL
24	NULL
h.	NULL
The	NULL
contents	NULL
of	NULL
the	NULL
wells	NULL
were	NULL
then	NULL
collected	NULL
and	NULL
centrifuged	NULL
at	NULL
900	NULL
%	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Supernatants	NULL
were	NULL
then	NULL
recovered	NULL
and	NULL
stored	NULL
at	NULL
-20	NULL
C	NULL
before	NULL
analysis	NULL
.	NULL

Cell	NULL
line	NULL
cultures	NULL
Two	NULL
types	NULL
of	NULL
clones	NULL
(	NULL
plus	NULL
and	NULL
minus	NULL
)	NULL
of	NULL
the	NULL
myeloid	NULL
monocytic	NULL
cell	NULL
line	NULL
,	NULL
U937	NULL
cells	NULL
,	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
from	NULL
Priscilla	NULL
Biswas	NULL
and	NULL
Guido	NULL
Poli	NULL
(	NULL
Ospedale	NULL
San	NULL
Raffaele	NULL
,	NULL
Immunopathogenesis	NULL
Unit	NULL
,	NULL
Milano	NULL
,	NULL
Italy	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
maintained	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Inc.	NULL
Belgium	NULL
)	NULL
with	NULL
10	NULL
%	NULL
steroid-free	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
100	NULL
U/mL	NULL
penicillin	NULL
,	NULL
100	NULL
ug/ml	NULL
streptomycin	NULL
sulfate	NULL
,	NULL
and	NULL
2	NULL
mmol	NULL
/L	NULL
glutamine	NULL
(	NULL
BioWhittaker	NULL
,	NULL
Inc.	NULL
)	NULL
at	NULL
37	NULL
C	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

The	NULL
FCS	NULL
was	NULL
treated	NULL
with	NULL
1	NULL
%	NULL
dextran-coated	NULL
charcoal	NULL
to	NULL
remove	NULL
endogenous	NULL
sex	NULL
steroids	NULL
and	NULL
glucocorticoids	NULL
.	NULL

Cells	NULL
were	NULL
counted	NULL
and	NULL
cultured	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
TNFa	NULL
(	NULL
10	NULL
ng/mL	NULL
)	NULL
or	NULL
IL-10	NULL
(	NULL
250	NULL
pg/mL	NULL
)	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
,	NULL
UK	NULL
)	NULL
for	NULL
24	NULL
h	NULL
and	NULL
48	NULL
h.	NULL
The	NULL
cells	NULL
were	NULL
then	NULL
treated	NULL
as	NULL
follows	NULL
:	NULL
1	NULL
)	NULL
The	NULL
cells	NULL
were	NULL
removed	NULL
,	NULL
counted	NULL
,	NULL
and	NULL
prepared	NULL
for	NULL
whole-cell	NULL
dexamethasone	NULL
binding	NULL
assay	NULL
;	NULL
2	NULL
)	NULL
The	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
phorbol-myristate-acetate	NULL
(	NULL
PMA	NULL
)	NULL
,	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
ng/mL	NULL
,	NULL
for	NULL
24	NULL
h	NULL
,	NULL
in	NULL
medium	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
(	NULL
107B	NULL
and	NULL
10	NULL
®	NULL
mol/L	NULL
)	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
then	NULL
recovered	NULL
and	NULL
stored	NULL
at	NULL
-20	NULL
C	NULL
before	NULL
further	NULL
analyses	NULL
.	NULL

Whole-cell	NULL
dexamethasone	NULL
binding	NULL
assay	NULL
A	NULL
whole-cell	NULL
dexamethasone	NULL
binding	NULL
assay	NULL
was	NULL
used	NULL
to	NULL
quantify	NULL
GR	NULL
number	NULL
and	NULL
to	NULL
determine	NULL
GR	NULL
affinity	NULL
in	NULL
untreated	NULL
and	NULL
TNFa-	NULL
or	NULL
IL-10-treated	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
,	NULL
in	NULL
a	NULL
waterbath	NULL
at	NULL
37	NULL
C	NULL
,	NULL
for	NULL
2	NULL
h	NULL
,	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
10	NULL
``	NULL
cells/mL	NULL
in	NULL
RPMI	NULL
1640	NULL
buffer	NULL
solution	NULL
containing	NULL
0.5	NULL
%	NULL
BSA	NULL
(	NULL
Sigma	NULL
,	NULL
Belgium	NULL
)	NULL
supplemented	NULL
with	NULL
seven	NULL
different	NULL
concentrations	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-dexamethasone	NULL
(	NULL
Amersham	NULL
International	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
ranging	NULL
from	NULL
2.5-50	NULL
nmol/L	NULL
(	NULL
SA	NULL
,	NULL
82	NULL
Ci/mmol	NULL
)	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
1000-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
dexamethasone	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
cooled	NULL
,	NULL
centrifuged	NULL
,	NULL
and	NULL
washed	NULL
before	NULL
the	NULL
supernatant	NULL
was	NULL
carefully	NULL
aspired	NULL
.	NULL

Cells	NULL
were	NULL
resus-pended	NULL
in	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
scintillation	NULL
cocktail	NULL
for	NULL
counting	NULL
.	NULL

Dissociation	NULL
constant	NULL
(	NULL
K	NULL
,	NULL
,	NULL
)	NULL
values	NULL
and	NULL
receptor	NULL
binding	NULL
capacity	NULL
were	NULL
determined	NULL
on	NULL
the	NULL
basis	NULL
of	NULL
saturation	NULL
curves	NULL
using	NULL
nonlinear	NULL
regression	NULL
computed	NULL
with	NULL
the	NULL
Prism	NULL
2.0	NULL
program	NULL
(	NULL
GraphPad	NULL
Software	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

Sta-	NULL
2835	NULL
tistical	NULL
analyses	NULL
were	NULL
performed	NULL
on	NULL
the	NULL
Scatchard	NULL
analysis	NULL
of	NULL
the	NULL
same	NULL
curves	NULL
.	NULL

Immunoassays	NULL
Specific	NULL
enzyme-linked	NULL
immunosorbent	NULL
assays	NULL
were	NULL
used	NULL
to	NULL
measure	NULL
human	NULL
TNFa	NULL
,	NULL
IL-10	NULL
,	NULL
and	NULL
IL-6	NULL
(	NULL
Biosource	NULL
Technologies	NULL
,	NULL
Inc.	NULL
/Medgenix	NULL
,	NULL
Belgium	NULL
)	NULL
and	NULL
IL-1	NULL
Ra	NULL
(	NULL
receptor	NULL
antagonist	NULL
)	NULL
(	NULL
R	NULL
&	NULL
D	NULL
Systems	NULL
)	NULL
and	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Absorbency	NULL
was	NULL
transformed	NULL
to	NULL
cytokine	NULL
concentration	NULL
using	NULL
a	NULL
standard	NULL
curve	NULL
computed	NULL
with	NULL
Medgenix	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
software	NULL
.	NULL

Statistical	NULL
analyses	NULL
The	NULL
relative	NULL
changes	NULL
of	NULL
cytokine	NULL
production	NULL
were	NULL
computed	NULL
for	NULL
each	NULL
dexamethasone	NULL
dose	NULL
.	NULL

A	NULL
logarithmic	NULL
transformation	NULL
was	NULL
used	NULL
for	NULL
the	NULL
percentage	NULL
of	NULL
response	NULL
,	NULL
to	NULL
normalize	NULL
the	NULL
distribution	NULL
.	NULL

A	NULL
generalized	NULL
linear	NULL
mixed	NULL
model	NULL
(	NULL
SAS	NULL
PROC	NULL
MIXED	NULL
)	NULL
was	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
dexamethasone	NULL
general	NULL
effect	NULL
and	NULL
the	NULL
specific-dose	NULL
effect	NULL
on	NULL
cytokine	NULL
secretion	NULL
.	NULL

All	NULL
results	NULL
were	NULL
considered	NULL
to	NULL
be	NULL
significant	NULL
at	NULL
the	NULL
5	NULL
%	NULL
critical	NULL
level	NULL
(	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Statistical	NULL
analyses	NULL
were	NULL
carried	NULL
out	NULL
using	NULL
the	NULL
SAS	NULL
software	NULL
package	NULL
(	NULL
SAS	NULL
Institute	NULL
,	NULL
Inc.	NULL
,	NULL
Cary	NULL
,	NULL
NC	NULL
)	NULL
.	NULL

Nonparametric	NULL
(	NULL
Mann	NULL
Withney	NULL
and	NULL
Wilcoxon	NULL
tests	NULL
)	NULL
and	NULL
parametric	NULL
tests	NULL
(	NULL
Student	NULL
's	NULL
t	NULL
and	NULL
ANOVA	NULL
tests	NULL
)	NULL
were	NULL
also	NULL
used	NULL
for	NULL
comparisons	NULL
,	NULL
as	NULL
appropriate	NULL
.	NULL

Results	NULL
Dexamethasone	NULL
modulates	NULL
TNFa	NULL
and	NULL
IL-10	NULL
secretion	NULL
in	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
TNFa	NULL
and	NULL
IL-10	NULL
secretion	NULL
were	NULL
significantly	NULL
increased	NULL
in	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

Although	NULL
both	NULL
absolute	NULL
and	NULL
percent	NULL
baseline	NULL
values	NULL
are	NULL
shown	NULL
,	NULL
only	NULL
the	NULL
statistical	NULL
comparisons	NULL
between	NULL
cytokine	NULL
levels	NULL
expressed	NULL
as	NULL
mean	NULL
percent	NULL
baseline	NULL
are	NULL
reported	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

TNFa	NULL
secretion	NULL
was	NULL
uniformly	NULL
suppressed	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
by	NULL
dexamethasone	NULL
(	NULL
10	NULL
°-10~°	NULL
mol/L	NULL
)	NULL
after	NULL
three	NULL
different	NULL
concentrations	NULL
of	NULL
LPS	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
middle	NULL
and	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
the	NULL
dexamethasone-induced	NULL
inhibition	NULL
of	NULL
TNFa	NULL
at	NULL
107°	NULL
and	NULL
107	NULL
``	NULL
mol/L	NULL
was	NULL
less	NULL
marked	NULL
after	NULL
1	NULL
and	NULL
10	NULL
ng	NULL
than	NULL
after	NULL
0.1	NULL
ng	NULL
LPS	NULL
stimulation	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
IL-10	NULL
secretion	NULL
was	NULL
biphasic	NULL
,	NULL
characterized	NULL
by	NULL
stimulation	NULL
at	NULL
the	NULL
lower	NULL
doses	NULL
employed	NULL
and	NULL
inhibition	NULL
at	NULL
the	NULL
higher	NULL
doses	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
left	NULL
and	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

LPS	NULL
dose	NULL
effects	NULL
on	NULL
dexamethasone-induced	NULL
changes	NULL
in	NULL
IL-10	NULL
secretion	NULL
were	NULL
ob-served	NULL
,	NULL
;	NULL
IL-10	NULL
was	NULL
strongly	NULL
suppressed	NULL
by	NULL
dexamethasone	NULL
(	NULL
10~°-10~°	NULL
mol/L	NULL
)	NULL
after	NULL
0.1	NULL
ng	NULL
LPS	NULL
stimulation	NULL
,	NULL
whereas	NULL
its	NULL
secretion	NULL
was	NULL
biphasic	NULL
after	NULL
1	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
LPS	NULL
stimulation	NULL
(	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

After	NULL
exposure	NULL
to	NULL
1	NULL
and	NULL
10	NULL
ng	NULL
LPS	NULL
,	NULL
there	NULL
was	NULL
no	NULL
difference	NULL
in	NULL
IL-10	NULL
modulation	NULL
by	NULL
dexamethasone	NULL
at	NULL
10~°	NULL
and	NULL
10~°	NULL
mol/L	NULL
;	NULL
however	NULL
,	NULL
a	NULL
significant	NULL
difference	NULL
appeared	NULL
at	NULL
10~	NULL
``	NULL
and	NULL
10~°	NULL
mol/L	NULL
glucocorticoid	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
and	NULL
P	NULL
<	NULL
0.05	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

At	NULL
each	NULL
of	NULL
the	NULL
three	NULL
concentrations	NULL
of	NULL
LPS	NULL
employed	NULL
,	NULL
the	NULL
dexamethasone-induced	NULL
modulation	NULL
(	NULL
10	NULL
°-10~°	NULL
mol/L	NULL
)	NULL
was	NULL
significantly	NULL
different	NULL
between	NULL
IL-10	NULL
and	NULL
TNFa	NULL
(	NULL
P	NULL
<	NULL
0.05-0.001	NULL
)	NULL
.	NULL

After	NULL
0.1	NULL
ng	NULL
LPS	NULL
,	NULL
however	NULL
,	NULL
no	NULL
difference	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
dexamethasone-induced	NULL
modulation	NULL
of	NULL
IL-10	NULL
and	NULL
TNFa	NULL
secretion	NULL
at	NULL
10~	NULL
``	NULL
and	NULL
10~°	NULL
mol/L	NULL
glucocorticoid	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

The	NULL
results	NULL
were	NULL
similar	NULL
at	NULL
both	NULL
24-	NULL
and	NULL
48-h	NULL
incubations	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

TNFa	NULL
and	NULL
IL-10	NULL
modulate	NULL
dexamethasone-mediated	NULL
IL-6	NULL
suppression	NULL
in	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
We	NULL
used	NULL
the	NULL
same	NULL
TNFa	NULL
and	NULL
IL-10	NULL
concentrations	NULL
that	NULL
were	NULL
observed	NULL
in	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
2836	NULL
FRANCHIMONT	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
(	NULL
24	NULL
h	NULL
)	NULL
100	NULL
|	NULL
3500-I	NULL
aso-80	NULL
-	NULL
3000-7	NULL
00	NULL
aay	NULL
&	NULL
sok	NULL
E	NULL
3	NULL
g	NULL
2007	NULL
~C	NULL
``	NULL
~	NULL
5	NULL
th	NULL
2D	NULL
2500	NULL
-	NULL
5	NULL
2	NULL
,	NULL
&	NULL
2	NULL
,	NULL
<	NULL
~*	NULL
a	NULL
s	NULL
``	NULL
7	NULL
A	NULL
5	NULL
8	NULL
-3	NULL
aB	NULL
'	NULL
3	NULL
2000	NULL
-	NULL
a	NULL
1507	NULL
o	NULL
+	NULL
\a	NULL
o	NULL
o	NULL
3	NULL
F	NULL
&	NULL
3	NULL
o	NULL
3	NULL
Al	NULL
gk	NULL
3	NULL
®	NULL
40	NULL
-	NULL
*	NULL
=	NULL
1500-1	NULL
8	NULL
6.	NULL
a	NULL
``	NULL
§	NULL
é	NULL
o	NULL
S	NULL
100-	NULL
&	NULL
y	NULL
>	NULL
LE	NULL
8	NULL
-	NULL
E	NULL
lL	NULL
%	NULL
_	NULL
-	NULL
_I	NULL
a	NULL
2	NULL
1000-	NULL
&	NULL
20	NULL
-	NULL
\	NULL
§	NULL
A	NULL
50	NULL
``	NULL
p	NULL
500-D	NULL
-~g	NULL
0	NULL
m-	NULL
-t	NULL
1	NULL
1	NULL
0	NULL
T	NULL
--	NULL
T	NULL
--	NULL
t	NULL
-	NULL
-+	NULL
7	NULL
0	NULL
0	NULL
-g	NULL
80-7	NULL
0	NULL
-6	NULL
0	NULL
-g	NULL
O80	NULL
70-6	NULL
B	NULL
(	NULL
48	NULL
h	NULL
)	NULL
100	NULL
1	NULL
3500-1	NULL
250-4	NULL
80-	NULL
§	NULL
3000-m	NULL
5	NULL
l	NULL
m	NULL
€	NULL
ire	NULL
!	NULL

a	NULL
200-g	NULL
4	NULL
*	NULL
g	NULL
2	NULL
tb	NULL
L	NULL
sb	NULL
2500	NULL
-	NULL
8	NULL
S	NULL
}	NULL
S	NULL
a	NULL
.	NULL

=	NULL
607	NULL
\	NULL
.	NULL

a	NULL
fo	NULL
6	NULL
®	NULL
159-8	NULL
#	NULL
A.	NULL
é	NULL
'	NULL
3	NULL
2000-	NULL
«	NULL
£	NULL
150	NULL
O	NULL
t	NULL
O	NULL
0	NULL
3	NULL
i	NULL
3	NULL
i	NULL
C	NULL
A\	NULL
TC	NULL
B	NULL
s	NULL
T	NULL
}	NULL
2	NULL
1500-	NULL
8	NULL
a	NULL
,	NULL
407	NULL
bok	NULL
A	NULL
.	NULL

8	NULL
um..	NULL
=	NULL
}	NULL
5	NULL
100	NULL
2	NULL
..\	NULL
``	NULL
5	NULL
.	NULL

8	NULL
8	NULL
1	NULL
-	NULL
I	NULL
;	NULL
E	NULL
5	NULL
p	NULL
§	NULL
A	NULL
E	NULL
1000-	NULL
A	NULL
,	NULL
R	NULL
:	NULL
\	NULL
20-	NULL
,	NULL
\	NULL
50-*f	NULL
500-4	NULL
:	NULL
A_	NULL
®	NULL
&	NULL
07	NULL
~	NULL
0	NULL
T	NULL
-T	NULL
1	NULL
l	NULL
o	NULL
-g	NULL
-80	NULL
70-6	NULL
0	NULL
O9	NULL
-B	NULL
70	NULL
-6	NULL
Dexamethasone	NULL
log	NULL
[	NULL
M	NULL
]	NULL
Dexamethasone	NULL
log	NULL
[	NULL
M	NULL
]	NULL
Dexamethasone	NULL
log	NULL
[	NULL
M	NULL
]	NULL
IL-10	NULL
TNF	NULL
-	NULL
.	NULL

D..	NULL
LQ	NULL
.	NULL

LPS	NULL
ing	NULL
_A..	NULL
LPS10ng	NULL
|	NULL
==C	NULL
&	NULL
=	NULL
LPSOlng	NULL
«	NULL
=O	NULL
LPS	NULL
Ing	NULL
«	NULL
=f	NULL
»	NULL
LPS	NULL
10	NULL
ng	NULL
JCE	NULL
&	NULL
M	NULL
»	NULL
1999	NULL
Vol	NULL
84	NULL
«	NULL
No	NULL
8	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Dexamethasone	NULL
effects	NULL
on	NULL
the	NULL
LPS-stimulated	NULL
secretion	NULL
of	NULL
TNFa	NULL
or	NULL
IL-10	NULL
in	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
from	NULL
male	NULL
normal	NULL
volunteers	NULL
.	NULL

Data	NULL
are	NULL
expressed	NULL
as	NULL
mean	NULL
+	NULL
SEM	NULL
.	NULL

Modulation	NULL
is	NULL
presented	NULL
as	NULL
mean	NULL
absolute	NULL
cytokine	NULL
levels	NULL
and	NULL
middle	NULL
panels	NULL
)	NULL
and	NULL
as	NULL
mean	NULL
percent	NULL
baseline	NULL
(	NULL
right	NULL
panels	NULL
)	NULL
after	NULL
an	NULL
incubation	NULL
of	NULL
24	NULL
h	NULL
(	NULL
A	NULL
)	NULL
or	NULL
48	NULL
h	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
statistical	NULL
comparisons	NULL
of	NULL
cytokine	NULL
levels	NULL
are	NULL
shown	NULL
only	NULL
for	NULL
the	NULL
mean	NULL
percent	NULL
baseline	NULL
data	NULL
(	NULL
right	NULL
panels	NULL
)	NULL
.	NULL

Dexamethasone	NULL
suppressed	NULL
TNFa	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
.	NULL

By	NULL
contrast	NULL
,	NULL
its	NULL
effect	NULL
on	NULL
IL-10	NULL
secretion	NULL
was	NULL
biphasic	NULL
,	NULL
producing	NULL
a	NULL
stimulation	NULL
at	NULL
the	NULL
lower	NULL
doses	NULL
employed	NULL
and	NULL
an	NULL
inhibition	NULL
at	NULL
the	NULL
higher	NULL
doses	NULL
.	NULL

At	NULL
each	NULL
of	NULL
the	NULL
three	NULL
concentrations	NULL
of	NULL
LPS	NULL
stimulation	NULL
employed	NULL
,	NULL
the	NULL
dexamethasone-induced	NULL
modulation	NULL
at	NULL
10	NULL
*-10	NULL
®	NULL
mol/L	NULL
was	NULL
significantly	NULL
different	NULL
between	NULL
TNFa	NULL
and	NULL
IL-10	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
;	NULL
**	NULL
,	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

A	NULL
LPS	NULL
dose-dependent	NULL
modulation	NULL
of	NULL
the	NULL
IL-10	NULL
secretion	NULL
by	NULL
dexamethasone	NULL
from	NULL
10	NULL
*-10~®	NULL
mol/L	NULL
was	NULL
observed	NULL
:	NULL
IL-10	NULL
was	NULL
strongly	NULL
suppressed	NULL
after	NULL
0.1	NULL
ng	NULL
LPS	NULL
stimulation	NULL
by	NULL
the	NULL
higher	NULL
doses	NULL
of	NULL
dexamethasone	NULL
(	NULL
10	NULL
*-10~®	NULL
mol/L	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
IL-10	NULL
secretion	NULL
was	NULL
biphasic	NULL
after	NULL
1	NULL
ng	NULL
and	NULL
10	NULL
ng	NULL
LPS	NULL
stimulation	NULL
(	NULL
00	NULL
,	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
.	NULL

(	NULL
1	NULL
ng/mL	NULL
.	NULL

and	NULL
50	NULL
pg/mL	NULL
,	NULL
respectively	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
and	NULL
investigated	NULL
whether	NULL
TNFa	NULL
or	NULL
IL-10	NULL
preincubation	NULL
could	NULL
change	NULL
the	NULL
sensitivity	NULL
to	NULL
dexamethasone	NULL
assessed	NULL
by	NULL
dexamethasone-mediated	NULL
IL-6	NULL
inhibition	NULL
in	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
from	NULL
10	NULL
healthy	NULL
subjects	NULL
.	NULL

The	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
exposed	NULL
to	NULL
TNFa	NULL
or	NULL
IL-10	NULL
did	NULL
not	NULL
produce	NULL
IL-6	NULL
.	NULL

After	NULL
LPS	NULL
stimulation	NULL
,	NULL
however	NULL
,	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
not	NULL
exposed	NULL
to	NULL
either	NULL
cytokine	NULL
secreted	NULL
more	NULL
IL-6	NULL
(	NULL
399.8	NULL
+	NULL
29.2	NULL
pg/mL	NULL
.	NULL
)	NULL

than	NULL
when	NULL
GLUCOCORTICOID	NULL
,	NULL
TNFa	NULL
,	NULL
AND	NULL
IL-10	NULL
100	NULL
p	NULL
<	NULL
0.01	NULL
80	NULL
p	NULL
<	NULL
0.01	NULL
C	NULL
t	NULL
so-h	NULL
--	NULL
3	NULL
9	NULL
o	NULL
3	NULL
E	NULL
®	NULL
|	NULL
_e	NULL
I	NULL
uy	NULL
497	NULL
e	NULL
in	NULL
**	NULL
U	NULL
LU	NULL
U	NULL
L	NULL
20-7	NULL
eo	NULL
U	NULL
*	NULL
``	NULL
le	NULL
»	NULL
0	NULL
T	NULL
T	NULL
Medium	NULL
alone	NULL
Preincubation	NULL
with	NULL
IL-10	NULL
(	NULL
50	NULL
pg/ml	NULL
)	NULL
Preincubation	NULL
with	NULL
TNFa	NULL
(	NULL
1	NULL
ng/ml	NULL
)	NULL
Dexamethasone	NULL
10-8	NULL
M	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Low	NULL
doses	NULL
of	NULL
dexamethasone	NULL
suppressed	NULL
LPS-induced	NULL
IL-6	NULL
secretion	NULL
by	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
pretreated	NULL
with	NULL
TNFa	NULL
or	NULL
IL-10	NULL
.	NULL

The	NULL
former	NULL
diminished	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
latter	NULL
improved	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
dexamethasone	NULL
to	NULL
suppress	NULL
IL-6	NULL
secretion	NULL
,	NULL
changes	NULL
compatible	NULL
with	NULL
decreased	NULL
or	NULL
increased	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
,	NULL
respectively	NULL
.	NULL

exposed	NULL
to	NULL
TNFa	NULL
(	NULL
155.7	NULL
+	NULL
24.2	NULL
pg/mL	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
or	NULL
IL-10	NULL
(	NULL
232.6	NULL
+	NULL
44.8	NULL
pg/mL	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

Preincubation	NULL
with	NULL
TNFa	NULL
was	NULL
associated	NULL
with	NULL
a	NULL
lower	NULL
IL-6	NULL
secretion	NULL
than	NULL
preincubation	NULL
with	NULL
IL-10	NULL
(	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
.	NULL

A	NULL
longer	NULL
pretreatment	NULL
,	NULL
up	NULL
to	NULL
48	NULL
h	NULL
before	NULL
LPS	NULL
stimulation	NULL
,	NULL
was	NULL
associated	NULL
with	NULL
poor	NULL
IL-6	NULL
secretion	NULL
and	NULL
did	NULL
not	NULL
enable	NULL
us	NULL
to	NULL
assess	NULL
corticosensitivity	NULL
.	NULL

The	NULL
dexamethasone-mediated	NULL
IL-6	NULL
inhibition	NULL
was	NULL
stronger	NULL
after	NULL
preincubation	NULL
with	NULL
IL-10	NULL
(	NULL
18.9	NULL
+	NULL
1.5	NULL
%	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
and	NULL
weaker	NULL
after	NULL
preincubation	NULL
with	NULL
TNFa	NULL
(	NULL
58.5	NULL
+	NULL
2.1	NULL
%	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
than	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
41.1	NULL
+	NULL
1.83	NULL
%	NULL
)	NULL
.	NULL

TNFa	NULL
and	NULL
IL-10	NULL
modulate	NULL
dexamethasone-induced	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
by	NULL
a	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
We	NULL
examined	NULL
whether	NULL
TNFa	NULL
and	NULL
IL-10	NULL
preincubation	NULL
could	NULL
change	NULL
the	NULL
sensitivity	NULL
to	NULL
dexamethasone	NULL
assessed	NULL
by	NULL
dexamethasone-induced	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
in	NULL
the	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
.	NULL

In	NULL
the	NULL
baseline	NULL
condition	NULL
,	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
was	NULL
increased	NULL
after	NULL
both	NULL
TNFa	NULL
(	NULL
16.4	NULL
+	NULL
0.9	NULL
pg/mL	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
and	NULL
IL-10	NULL
(	NULL
10.1	NULL
+	NULL
0.6	NULL
pg/mL	NULL
,	NULL
P	NULL
<	NULL
0.01	NULL
)	NULL
preincu-bation	NULL
;	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
IL-1	NULL
Ra	NULL
level	NULL
was	NULL
observed	NULL
after	NULL
these	NULL
two	NULL
preincubations	NULL
.	NULL

After	NULL
PMA	NULL
stimulation	NULL
,	NULL
however	NULL
,	NULL
dexamethasone-induced	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
at	NULL
10~°	NULL
mol/L	NULL
was	NULL
higher	NULL
with	NULL
IL-10	NULL
preincubation	NULL
(	NULL
55.7	NULL
+	NULL
3.5	NULL
2837	NULL
70	NULL
-*-	NULL
Control	NULL
-i-	NULL
IL-10	NULL
(	NULL
250	NULL
pg/ml	NULL
)	NULL
3	NULL
so-	NULL
|	NULL
-¥-	NULL
TNFa	NULL
(	NULL
10	NULL
ng/ml	NULL
)	NULL
50	NULL
p	NULL
o	NULL
1	NULL
IL-1ra	NULL
(	NULL
pg/ml	NULL
)	NULL
8	NULL
20	NULL
0	NULL
T	NULL
i	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
0	NULL
-8	NULL
-6	NULL
Dexamethasone	NULL
log	NULL
[	NULL
M	NULL
]	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Dexamethasone	NULL
caused	NULL
a	NULL
dose-dependent	NULL
stimulation	NULL
of	NULL
IL-1Ra	NULL
in	NULL
human	NULL
monocytic	NULL
U937	NULL
cells	NULL
stimulated	NULL
with	NULL
PMA	NULL
.	NULL

This	NULL
response	NULL
was	NULL
decreased	NULL
by	NULL
preincubation	NULL
with	NULL
TNFa	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
but	NULL
was	NULL
enhanced	NULL
by	NULL
preincubation	NULL
with	NULL
IL-10	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

pg/ml	NULL
,	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
and	NULL
weaker	NULL
with	NULL
TNFa	NULL
preincubation	NULL
(	NULL
14.7	NULL
+	NULL
1.7	NULL
pg/mL	NULL
.	NULL

,	NULL
P	NULL
<	NULL
0.05	NULL
)	NULL
than	NULL
with	NULL
medium	NULL
alone	NULL
(	NULL
23.5	NULL
+	NULL
3.1	NULL
pg/mL	NULL
)	NULL
.	NULL

No	NULL
significant	NULL
difference	NULL
was	NULL
observed	NULL
between	NULL
the	NULL
IL-1	NULL
Ra	NULL
responses	NULL
of	NULL
plus	NULL
and	NULL
minus	NULL
clones	NULL
of	NULL
U937	NULL
cells	NULL
.	NULL

TNFa	NULL
decreases	NULL
,	NULL
and	NULL
IL-10	NULL
increases	NULL
,	NULL
the	NULL
GR	NULL
concentration	NULL
(	NULL
but	NULL
not	NULL
binding	NULL
affinity	NULL
)	NULL
in	NULL
a	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
To	NULL
assess	NULL
the	NULL
effect	NULL
of	NULL
TNFa	NULL
and	NULL
IL-10	NULL
on	NULL
the	NULL
GR	NULL
number	NULL
and	NULL
binding	NULL
affinity	NULL
,	NULL
we	NULL
used	NULL
dexamethasone	NULL
radioligand	NULL
binding	NULL
in	NULL
the	NULL
human	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
.	NULL

This	NULL
was	NULL
done	NULL
to	NULL
avoid	NULL
the	NULL
high	NULL
variability	NULL
observed	NULL
in	NULL
studies	NULL
of	NULL
isolated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
.	NULL

U937	NULL
cells	NULL
were	NULL
cultured	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
TNFa	NULL
or	NULL
IL-10	NULL
,	NULL
for	NULL
up	NULL
to	NULL
48	NULL
h	NULL
;	NULL
and	NULL
dexamethasone	NULL
binding	NULL
was	NULL
assessed	NULL
.	NULL

No	NULL
change	NULL
in	NULL
proliferation	NULL
rate	NULL
was	NULL
observed	NULL
between	NULL
the	NULL
different	NULL
preincubations	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Both	NULL
TNFa	NULL
and	NULL
IL-10	NULL
failed	NULL
to	NULL
induce	NULL
a	NULL
significant	NULL
modulation	NULL
of	NULL
the	NULL
GR	NULL
number	NULL
at	NULL
time	NULL
periods	NULL
less	NULL
than	NULL
48	NULL
h.	NULL
However	NULL
,	NULL
48-h	NULL
exposure	NULL
to	NULL
TNFa	NULL
resulted	NULL
in	NULL
a	NULL
60	NULL
%	NULL
decrease	NULL
of	NULL
the	NULL
GR	NULL
number	NULL
(	NULL
4,834	NULL
+	NULL
246	NULL
sites/cell	NULL
vs.	NULL
11,709	NULL
+	NULL
544	NULL
sites	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
without	NULL
any	NULL
change	NULL
of	NULL
the	NULL
binding	NULL
affinity	NULL
(	NULL
11.4	NULL
+	NULL
1.5	NULL
nmol/L	NULL
vs.	NULL
16.1	NULL
+	NULL
1.8	NULL
nmol/L	NULL
)	NULL
,	NULL
whereas	NULL
exposure	NULL
to	NULL
IL-10	NULL
resulted	NULL
in	NULL
a	NULL
50	NULL
%	NULL
increase	NULL
of	NULL
the	NULL
GR	NULL
numbers	NULL
(	NULL
17,734	NULL
+	NULL
87	NULL
sites	NULL
vs.	NULL
11,709	NULL
+	NULL
544	NULL
sites	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
also	NULL
without	NULL
any	NULL
change	NULL
2838	NULL
20	NULL
FRANCHIMONT	NULL
ET	NULL
AL	NULL
.	NULL

JCE	NULL
&	NULL
M	NULL
»	NULL
1999	NULL
Vol	NULL
84	NULL
«	NULL
No	NULL
8	NULL
T	NULL
0	NULL
6	NULL
10	NULL
T	NULL
15	NULL
20	NULL
25	NULL
3	NULL
D	NULL
D	NULL
o	NULL
O	NULL
G	NULL
€	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Saturation	NULL
analyses	NULL
and	NULL
Scat-	NULL
“	NULL
é	NULL
Bound	NULL
PH	NULL
}	NULL
-dexamethasone	NULL
a	NULL
chard	NULL
plots	NULL
(	NULL
inset	NULL
)	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
-dexametha-	NULL
9	NULL
(	NULL
fimol/10®	NULL
ceils	NULL
)	NULL
A	NULL
sone	NULL
binding	NULL
in	NULL
human	NULL
monocytic	NULL
U937	NULL
3	NULL
10	NULL
=	NULL
cells	NULL
pretreated	NULL
with	NULL
TNFa	NULL
or	NULL
IL-10	NULL
.	NULL

m	NULL
|	NULL
®	NULL
The	NULL
former	NULL
decreased	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
0.001	NULL
)	NULL
,	NULL
g	NULL
a	NULL
whereas	NULL
the	NULL
latter	NULL
increased	NULL
(	NULL
*	NULL
,	NULL
P	NULL
<	NULL
»	NULL
a	NULL
0.001	NULL
)	NULL
the	NULL
concentration	NULL
of	NULL
dexametha-	NULL
FE	NULL
``	NULL
)	NULL
;	NULL
.m	NULL
sone	NULL
binding	NULL
sites	NULL
.	NULL

Results	NULL
are	NULL
from	NULL
E	NULL
Yol	NULL
gel	NULL
ugs	NULL
gcc	NULL
aac	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

a	NULL
A	NULL
V	NULL
fuss	NULL
suse	NULL
C	NULL
T	NULL
Y	NULL
-	NULL
510000	NULL
w	NULL
y	NULL
g	NULL
*J	NULL
-	NULL
#	NULL
00000	NULL
Tle	NULL
g	NULL
Fuer	NULL
``	NULL
w	NULL
-a-	NULL
_	NULL
Control	NULL
Patin	NULL
/	NULL
m	NULL
¢	NULL
``	NULL
C	NULL
-a-	NULL
IL-10	NULL
x	NULL
'	NULL
v	NULL
--	NULL
-+	NULL
--	NULL
TNFa	NULL
0	NULL
1	NULL
.	NULL

m	NULL
r	NULL
0	NULL
10	NULL
20	NULL
-	NULL
30	NULL
40	NULL
50	NULL
TABLE	NULL
1	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
IL-10	NULL
and	NULL
TNFa	NULL
on	NULL
dexamethasone	NULL
binding	NULL
sites	NULL
in	NULL
U937	NULL
cells	NULL
Binding	NULL
sites/cell	NULL
(	NULL
Bmax	NULL
)	NULL
K	NULL
;	NULL
(	NULL
nm	NULL
)	NULL
Control	NULL
(	NULL
n	NULL
=	NULL
8	NULL
)	NULL
11,709	NULL
+	NULL
544	NULL
16.1	NULL
+	NULL
1.8	NULL
IL-10	NULL
preincubation	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
17,734	NULL
+	NULL
87°	NULL
21.5	NULL
+	NULL
2.4	NULL
TNFa	NULL
preincubation	NULL
(	NULL
n	NULL
=	NULL
3	NULL
)	NULL
4,834	NULL
+	NULL
246°	NULL
11.4	NULL
+	NULL
1.5	NULL
*	NULL
Bmax	NULL
,	NULL
P	NULL
<	NULL
0.001.	NULL
of	NULL
the	NULL
binding	NULL
affinity	NULL
(	NULL
21.5	NULL
+	NULL
2.4	NULL
nmol/L	NULL
vs.	NULL
16.1	NULL
+	NULL
1.8	NULL
nmol/L	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
summarized	NULL
on	NULL
Table	NULL
1	NULL
.	NULL

Discussion	NULL
Although	NULL
glucocorticoids	NULL
clearly	NULL
suppress	NULL
proinflammatory	NULL
cytokines	NULL
,	NULL
they	NULL
have	NULL
been	NULL
reported	NULL
not	NULL
to	NULL
change	NULL
(	NULL
16	NULL
,	NULL
19	NULL
)	NULL
,	NULL
to	NULL
increase	NULL
(	NULL
17	NULL
)	NULL
,	NULL
or	NULL
to	NULL
decrease	NULL
IL-10	NULL
secretion	NULL
(	NULL
18	NULL
,	NULL
21	NULL
)	NULL
.	NULL

An	NULL
in	NULL
vivo	NULL
increase	NULL
of	NULL
plasma	NULL
IL-10	NULL
by	NULL
exogenous	NULL
glucocorticoids	NULL
was	NULL
previously	NULL
reported	NULL
both	NULL
in	NULL
human	NULL
and	NULL
murine	NULL
endo-toxemia	NULL
(	NULL
22	NULL
,	NULL
23	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
observed	NULL
a	NULL
biphasic	NULL
effect	NULL
of	NULL
glucocorticoids	NULL
on	NULL
IL-10	NULL
secretion	NULL
by	NULL
LPS-stimulated	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
.	NULL

Depending	NULL
on	NULL
the	NULL
amplitude	NULL
of	NULL
LPS	NULL
stimulation	NULL
,	NULL
glucocorticoids	NULL
at	NULL
low	NULL
doses	NULL
increased	NULL
,	NULL
and	NULL
at	NULL
high	NULL
doses	NULL
decreased	NULL
,	NULL
IL-10	NULL
secretion	NULL
;	NULL
in	NULL
contrast	NULL
,	NULL
TNFa	NULL
secretion	NULL
was	NULL
always	NULL
suppressed	NULL
by	NULL
dexamethasone	NULL
in	NULL
a	NULL
classic	NULL
sigmoidal	NULL
fashion	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
monocyte/macro-phage	NULL
activation	NULL
modulates	NULL
the	NULL
effect	NULL
of	NULL
dexamethasone	NULL
on	NULL
IL-10	NULL
secretion	NULL
,	NULL
whereas	NULL
the	NULL
direction	NULL
of	NULL
the	NULL
TNFa	NULL
response	NULL
to	NULL
glucocorticoids	NULL
remains	NULL
unchanged	NULL
.	NULL

cAMP-elevating	NULL
drugs	NULL
increase	NULL
IL-10	NULL
and	NULL
decrease	NULL
TNFa	NULL
secretion	NULL
(	NULL
24	NULL
)	NULL
,	NULL
and	NULL
cAMP-responsive	NULL
elements	NULL
have	NULL
been	NULL
described	NULL
in	NULL
both	NULL
the	NULL
IL-10	NULL
and	NULL
TNFa	NULL
promoters	NULL
(	NULL
25	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
GR	NULL
interacts	NULL
with	NULL
cAMP-responsive	NULL
element-binding	NULL
protein	NULL
,	NULL
and	NULL
this	NULL
interaction	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
differential	NULL
modulation	NULL
of	NULL
IL-10	NULL
and	NULL
TNFa	NULL
secretion	NULL
by	NULL
glucocorticoids	NULL
(	NULL
27	NULL
)	NULL
.	NULL

IL-1Ra	NULL
is	NULL
a	NULL
receptor-level	NULL
natural	NULL
antagonist	NULL
of	NULL
IL-1	NULL
that	NULL
was	NULL
isolated	NULL
from	NULL
monocytes	NULL
and	NULL
monocytic	NULL
cell	NULL
lines	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Free	NULL
[	NULL
PH	NULL
]	NULL
-dexamethasone	NULL
(	NULL
nM	NULL
)	NULL
Glucocorticoids	NULL
inhibit	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
by	NULL
LPS-stimulated	NULL
human	NULL
peripheral	NULL
monocytes	NULL
(	NULL
29	NULL
)	NULL
but	NULL
potentiate	NULL
the	NULL
IL-1B	NULL
secretory	NULL
response	NULL
of	NULL
monocytic	NULL
cells	NULL
to	NULL
PMA	NULL
(	NULL
30	NULL
)	NULL
.	NULL

The	NULL
PMA-differentiated	NULL
monocytic	NULL
cell	NULL
line	NULL
U937	NULL
produces	NULL
IL-1Ra	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Here	NULL
,	NULL
we	NULL
demonstrated	NULL
that	NULL
dexamethasone	NULL
increased	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
by	NULL
these	NULL
cells	NULL
,	NULL
providing	NULL
an	NULL
additional	NULL
explanation	NULL
for	NULL
an	NULL
indirect	NULL
antiinflammatory	NULL
action	NULL
for	NULL
glucocorticoids	NULL
.	NULL

Preincubation	NULL
with	NULL
TNFa	NULL
or	NULL
IL-10	NULL
modulated	NULL
the	NULL
sensitivity	NULL
to	NULL
dexamethasone	NULL
in	NULL
both	NULL
normal	NULL
leukocytes	NULL
present	NULL
in	NULL
whole-blood	NULL
cell	NULL
cultures	NULL
and	NULL
U937	NULL
cells	NULL
.	NULL

Both	NULL
TNFa	NULL
and	NULL
IL-10	NULL
inhibited	NULL
IL-6	NULL
and	NULL
enhanced	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
dexamethasone	NULL
;	NULL
however	NULL
,	NULL
their	NULL
effects	NULL
were	NULL
in	NULL
opposite	NULL
directions	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
.	NULL

Thus	NULL
,	NULL
whereas	NULL
IL-6	NULL
was	NULL
more	NULL
inhibited	NULL
by	NULL
TNFa	NULL
than	NULL
by	NULL
IL-10	NULL
at	NULL
the	NULL
baseline	NULL
state	NULL
,	NULL
dexamethasone-mediated	NULL
IL-6	NULL
inhibition	NULL
was	NULL
less	NULL
prominent	NULL
after	NULL
TNFa	NULL
incubation	NULL
than	NULL
after	NULL
IL-10	NULL
incubation	NULL
.	NULL

Similarly	NULL
,	NULL
whereas	NULL
IL-1	NULL
Ra	NULL
secretion	NULL
was	NULL
slightly	NULL
more	NULL
stimulated	NULL
by	NULL
TNFa	NULL
than	NULL
by	NULL
IL-10	NULL
at	NULL
the	NULL
baseline	NULL
state	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
dexamethasone	NULL
,	NULL
it	NULL
was	NULL
blocked	NULL
by	NULL
TNFa	NULL
and	NULL
dramatically	NULL
enhanced	NULL
by	NULL
IL-10	NULL
preincubation	NULL
.	NULL

IL-10	NULL
increased	NULL
,	NULL
and	NULL
TNFa	NULL
decreased	NULL
,	NULL
the	NULL
GR	NULL
concentration	NULL
of	NULL
U937	NULL
cells	NULL
without	NULL
modifying	NULL
its	NULL
binding	NULL
affinity	NULL
for	NULL
dexamethasone	NULL
.	NULL

Previously	NULL
,	NULL
some	NULL
cytokines	NULL
(	NULL
such	NULL
as	NULL
IFNy	NULL
)	NULL
were	NULL
shown	NULL
to	NULL
increase	NULL
sensitivity	NULL
of	NULL
cells	NULL
to	NULL
glucocorticoids	NULL
by	NULL
increasing	NULL
the	NULL
receptor	NULL
concentration	NULL
(	NULL
6	NULL
)	NULL
,	NULL
whereas	NULL
other	NULL
cytokines	NULL
(	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
IL-4	NULL
,	NULL
and	NULL
IL-13	NULL
)	NULL
decreased	NULL
sensitivity	NULL
by	NULL
decreasing	NULL
its	NULL
binding	NULL
affinity	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

MIF	NULL
,	NULL
the	NULL
macrophage	NULL
migration	NULL
inhibitory	NULL
factor	NULL
,	NULL
is	NULL
regulated	NULL
by	NULL
glucocorticoids	NULL
like	NULL
IL-10	NULL
;	NULL
however	NULL
,	NULL
unlike	NULL
IL-10	NULL
,	NULL
it	NULL
blocks	NULL
dexamethasone-mediated	NULL
inhibition	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
LPS-stimulated	NULL
monocytes	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Our	NULL
study	NULL
suggests	NULL
that	NULL
IL-10	NULL
may	NULL
enhance	NULL
glucocorticoid	NULL
action	NULL
by	NULL
increasing	NULL
the	NULL
GR	NULL
concen-tration	NULL
,	NULL
whereas	NULL
TNFa	NULL
may	NULL
exert	NULL
the	NULL
opposite	NULL
effect	NULL
by	NULL
decreasing	NULL
the	NULL
GR	NULL
concentration	NULL
.	NULL

Changes	NULL
in	NULL
the	NULL
receptor	NULL
may	NULL
be	NULL
one	NULL
of	NULL
several	NULL
mechanisms	NULL
for	NULL
altering	NULL
tissue	NULL
sensitivity	NULL
GLUCOCORTICOID	NULL
,	NULL
TNFa	NULL
,	NULL
AND	NULL
IL-10	NULL
to	NULL
glucocorticoids	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Indeed	NULL
,	NULL
the	NULL
modulation	NULL
of	NULL
dexamethasone	NULL
response	NULL
by	NULL
cytokines	NULL
may	NULL
also	NULL
be	NULL
related	NULL
to	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
many	NULL
proinflammatory	NULL
cytokines	NULL
,	NULL
including	NULL
IL-6	NULL
,	NULL
and	NULL
is	NULL
highly	NULL
expressed	NULL
in	NULL
inflamed	NULL
tissues	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Glucocorticoids	NULL
and	NULL
IL-10	NULL
inhibit	NULL
NFE-	NULL
«	NULL
B	NULL
activation	NULL
,	NULL
whereas	NULL
TNFa	NULL
activates	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
32-34	NULL
)	NULL
.	NULL

The	NULL
opposite	NULL
effect	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
modulation	NULL
exerted	NULL
by	NULL
TNFa	NULL
and	NULL
IL-10	NULL
may	NULL
also	NULL
provide	NULL
an	NULL
additional	NULL
explanation	NULL
for	NULL
the	NULL
opposite	NULL
effects	NULL
of	NULL
these	NULL
cytokines	NULL
on	NULL
glucocorticoid	NULL
sensitivity	NULL
described	NULL
here	NULL
.	NULL

In	NULL
Crohn	NULL
's	NULL
disease	NULL
,	NULL
blocking	NULL
TNFa	NULL
with	NULL
humanized	NULL
antibody	NULL
(	NULL
cA2	NULL
)	NULL
or	NULL
administering	NULL
IL-10	NULL
were	NULL
found	NULL
to	NULL
be	NULL
useful	NULL
adjunctive	NULL
therapies	NULL
(	NULL
35	NULL
,	NULL
36	NULL
)	NULL
.	NULL

Because	NULL
TNFa	NULL
decreases	NULL
,	NULL
and	NULL
IL-10	NULL
increases	NULL
,	NULL
sensitivity	NULL
to	NULL
dexamethasone	NULL
,	NULL
this	NULL
study	NULL
provides	NULL
evidence	NULL
for	NULL
another	NULL
potential	NULL
beneficial	NULL
indirect	NULL
effect	NULL
of	NULL
these	NULL
cytokine	NULL
therapies	NULL
.	NULL

This	NULL
also	NULL
suggests	NULL
that	NULL
the	NULL
balance	NULL
of	NULL
TNFa/IL-10	NULL
secretion	NULL
during	NULL
the	NULL
course	NULL
of	NULL
an	NULL
inflammatory	NULL
disease	NULL
may	NULL
determine	NULL
changes	NULL
in	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
.	NULL

Thus	NULL
,	NULL
a	NULL
patient	NULL
with	NULL
a	NULL
high	NULL
or	NULL
low	NULL
TNFa/	NULL
IL-10	NULL
ratio	NULL
would	NULL
,	NULL
respectively	NULL
,	NULL
be	NULL
less	NULL
or	NULL
more	NULL
sensitive	NULL
to	NULL
endogenous	NULL
and	NULL
exogenous	NULL
glucocorticoids	NULL
and	NULL
more	NULL
or	NULL
less	NULL
susceptible	NULL
to	NULL
develop	NULL
corticosteroid-resistant	NULL
and	NULL
-sensitive	NULL
inflammatory	NULL
disease	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Boumpas	NULL
DT	NULL
,	NULL
Chrousos	NULL
GP	NULL
,	NULL
Wilder	NULL
RL	NULL
,	NULL
Cupps	NULL
TR	NULL
,	NULL
Balow	NULL
JE	NULL
.	NULL

1993	NULL
Glucocorticoid	NULL
therapy	NULL
for	NULL
immune-mediated	NULL
diseases	NULL
:	NULL
basic	NULL
and	NULL
clinical	NULL
corre-lates	NULL
.	NULL

Ann	NULL
Intern	NULL
Med	NULL
.	NULL

119:1198-1208	NULL
.	NULL

2	NULL
.	NULL

Chrousos	NULL
GP	NULL
,	NULL
Castro	NULL
M	NULL
,	NULL
Leung	NULL
DM	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
Molecular	NULL
mechanisms	NULL
of	NULL
glucocorticoid	NULL
resistance	NULL
and	NULL
hypersensitivity	NULL
.	NULL

Am	NULL
]	NULL
Crit	NULL
Care	NULL
Med	NULL
.	NULL

154:539-544	NULL
.	NULL

3	NULL
.	NULL

Bamberger	NULL
CM	NULL
,	NULL
Schulte	NULL
HM	NULL
,	NULL
Chrousos	NULL
GP	NULL
.	NULL

1996	NULL
Molecular	NULL
determinants	NULL
of	NULL
glucocorticoid	NULL
receptor	NULL
,	NULL
function	NULL
and	NULL
tissue	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
.	NULL

En-doer	NULL
Rev	NULL
.	NULL

17:245-261	NULL
.	NULL

4	NULL
.	NULL

Chrousos	NULL
GP	NULL
,	NULL
Detera	NULL
S	NULL
,	NULL
Karl	NULL
M.	NULL
1993	NULL
Syndromes	NULL
of	NULL
glucocorticoid	NULL
resistance	NULL
.	NULL

Ann	NULL
Intern	NULL
Med	NULL
.	NULL

119:113-1124	NULL
.	NULL

5	NULL
.	NULL

Barnes	NULL
PJ	NULL
,	NULL
Karin	NULL
M.	NULL
1997	NULL
Nuclear	NULL
factor-kB	NULL
:	NULL
a	NULL
pivotal	NULL
transcription	NULL
factor	NULL
in	NULL
chronic	NULL
inflammatory	NULL
diseases	NULL
.	NULL

N	NULL
Eng	NULL
!	NULL

J	NULL
Med	NULL
.	NULL

336:1066-1071	NULL
.	NULL

6	NULL
.	NULL

Salkowski	NULL
CA	NULL
,	NULL
Vogel	NULL
SN	NULL
.	NULL

1992	NULL
IFNy	NULL
mediates	NULL
increased	NULL
glucocorticoid	NULL
receptor	NULL
expression	NULL
in	NULL
murine	NULL
macrophages	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

148:2770-2777	NULL
.	NULL

7	NULL
.	NULL

Kam	NULL
JC	NULL
,	NULL
Szefler	NULL
SJ	NULL
,	NULL
Surs	NULL
W	NULL
,	NULL
Sher	NULL
ER	NULL
,	NULL
Leung	NULL
DY	NULL
.	NULL

1993	NULL
Combination	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
reduces	NULL
glucocorticoid	NULL
receptor-binding	NULL
affinity	NULL
and	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
glucocorticoids	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

7:3460-3466	NULL
.	NULL

8	NULL
.	NULL

Spahn	NULL
DS	NULL
,	NULL
Szefler	NULL
J	NULL
,	NULL
Surs	NULL
W	NULL
,	NULL
Doherty	NULL
DE	NULL
,	NULL
Leung	NULL
DY	NULL
.	NULL

1996	NULL
A	NULL
novel	NULL
action	NULL
of	NULL
interleukin-13	NULL
:	NULL
induction	NULL
of	NULL
diminished	NULL
monocyte	NULL
glucocorticoid	NULL
receptor	NULL
binding	NULL
affinity	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

157:2654-2659	NULL
.	NULL

9	NULL
.	NULL

Costas	NULL
M	NULL
,	NULL
Trapp	NULL
Thorsen	NULL
,	NULL
Pereda	NULL
MP	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
Molecular	NULL
and	NULL
functional	NULL
evidence	NULL
for	NULL
in	NULL
vitro	NULL
cytokine	NULL
enhancement	NULL
of	NULL
human	NULL
and	NULL
murine	NULL
target	NULL
cell	NULL
sensitivity	NULL
to	NULL
glucocorticoids	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

98:1409-1416	NULL
.	NULL

10	NULL
.	NULL

Calandra	NULL
T	NULL
,	NULL
Bernhagen	NULL
J	NULL
,	NULL
Metz	NULL
CN	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
MIF	NULL
as	NULL
a	NULL
glucocorticoid-induced	NULL
modulator	NULL
of	NULL
cytokine	NULL
production	NULL
.	NULL

Nature	NULL
.	NULL

377:68-71	NULL
.	NULL

11	NULL
.	NULL

Mosmann	NULL
TR	NULL
,	NULL
Sad	NULL
$	NULL
.	NULL

1996	NULL
The	NULL
expanding	NULL
universe	NULL
of	NULL
T-cell	NULL
subsets	NULL
:	NULL
Th1	NULL
,	NULL
Th2	NULL
and	NULL
more	NULL
.	NULL

Immunol	NULL
Today	NULL
.	NULL

17:138-146	NULL
.	NULL

12	NULL
.	NULL

Fiorentino	NULL
DF	NULL
,	NULL
Zlotnick	NULL
A	NULL
,	NULL
Vieira	NULL
P	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1991	NULL
IL-10	NULL
acts	NULL
on	NULL
the	NULL
antigen	NULL
presenting	NULL
cells	NULL
to	NULL
inhibit	NULL
cytokine	NULL
production	NULL
by	NULL
Th-1	NULL
cells	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

146:3444-3451	NULL
.	NULL

13	NULL
.	NULL

Fiorentino	NULL
DF	NULL
,	NULL
Zlotnick	NULL
A	NULL
,	NULL
Mosmann	NULL
TR	NULL
,	NULL
Howard	NULL
M	NULL
,	NULL
Moore	NULL
KW	NULL
,	NULL
O'Garra	NULL
A	NULL
.	NULL

1991	NULL
IL-10	NULL
inhibits	NULL
cytokine	NULL
production	NULL
by	NULL
activated	NULL
macrophages	NULL
.	NULL
]	NULL

Immunol	NULL
.	NULL

147:3815-3822	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

2839	NULL
Moore	NULL
KW	NULL
,	NULL
O'Gatra	NULL
A	NULL
,	NULL
de	NULL
Waal	NULL
Malefyt	NULL
R	NULL
,	NULL
Vieira	NULL
P	NULL
,	NULL
Mosmann	NULL
TR	NULL
.	NULL

1993	NULL
Interleukin	NULL
10	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
.	NULL

11:165-190	NULL
.	NULL

Vassali	NULL
P.	NULL
1992	NULL
The	NULL
pathophysiology	NULL
of	NULL
tumor	NULL
necrosis	NULL
factors	NULL
.	NULL

Annu	NULL
Rev	NULL
Immunol	NULL
.	NULL

10:411-452	NULL
.	NULL

Elenkov	NULL
IJ	NULL
,	NULL
Papanicolaou	NULL
DA	NULL
,	NULL
Wilder	NULL
RL	NULL
,	NULL
Chrousos	NULL
GP	NULL
.	NULL

1996	NULL
Modulatory	NULL
effects	NULL
of	NULL
glucocorticoids	NULL
and	NULL
catecholamines	NULL
on	NULL
human	NULL
interleukin-12	NULL
and	NULL
interleukin-10	NULL
production	NULL
:	NULL
clinical	NULL
implications	NULL
.	NULL

Proc	NULL
Ass	NULL
Am	NULL
Phys	NULL
.	NULL

108:374-381	NULL
.	NULL

Blotta	NULL
MH	NULL
,	NULL
Dekruyff	NULL
RH	NULL
,	NULL
Umetsu	NULL
DT	NULL
.	NULL

1997	NULL
Corticosteroids	NULL
inhibit	NULL
IL-12	NULL
production	NULL
in	NULL
human	NULL
monocytes	NULL
and	NULL
enhance	NULL
their	NULL
capacity	NULL
to	NULL
induce	NULL
IL-4	NULL
synthesis	NULL
in	NULL
CD4+	NULL
lymphocytes	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

158:5589-5595	NULL
.	NULL

Franchimont	NULL
D	NULL
,	NULL
Louis	NULL
E	NULL
,	NULL
Martens	NULL
H	NULL
,	NULL
De	NULL
Groote	NULL
D	NULL
,	NULL
Belaiche	NULL
J	NULL
,	NULL
Geenen	NULL
V.	NULL
1998	NULL
Effects	NULL
of	NULL
dexamethasone	NULL
on	NULL
the	NULL
profile	NULL
of	NULL
cytokine	NULL
secretion	NULL
in	NULL
human	NULL
whole	NULL
blood	NULL
cell	NULL
cultures	NULL
.	NULL

Regul	NULL
Pept	NULL
.	NULL

73:59-65	NULL
.	NULL

Visser	NULL
J	NULL
,	NULL
Van	NULL
Boxel-Dezaire	NULL
A	NULL
,	NULL
Methorst	NULL
D	NULL
,	NULL
Brunt	NULL
T	NULL
,	NULL
de	NULL
Kloet	NULL
ER	NULL
,	NULL
Nagelkerken	NULL
L.	NULL
1998	NULL
Differential	NULL
regulation	NULL
of	NULL
interleukin-10	NULL
and	NULL
IL-12	NULL
by	NULL
glucocorticoids	NULL
in	NULL
vitro	NULL
.	NULL

Blood	NULL
.	NULL

91:4255-4264	NULL
.	NULL

De	NULL
Groote	NULL
D	NULL
,	NULL
Zangerle.F	NULL
,	NULL
Gevaert	NULL
Y	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1992	NULL
Direct	NULL
stimulation	NULL
of	NULL
cytokines	NULL
in	NULL
whole	NULL
blood	NULL
.	NULL

Comparison	NULL
with	NULL
isolated	NULL
PBMCs	NULL
stimulation	NULL
.	NULL

Cytokine	NULL
.	NULL

4:239-248	NULL
.	NULL

Fushimi	NULL
T	NULL
,	NULL
Okayama	NULL
H	NULL
,	NULL
Seki	NULL
T	NULL
,	NULL
Shimura	NULL
S	NULL
,	NULL
Shirato	NULL
K.	NULL
1997	NULL
Dexamethasone	NULL
suppresses	NULL
gene	NULL
expression	NULL
and	NULL
production	NULL
of	NULL
interleukin-10	NULL
by	NULL
human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
and	NULL
monocytes	NULL
.	NULL

Int	NULL
Arch	NULL
Allergy	NULL
Immunol	NULL
.	NULL

112:13-18	NULL
.	NULL

Marchant	NULL
A	NULL
,	NULL
Amaroui	NULL
Z	NULL
,	NULL
Gueydan	NULL
C	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
Methylprednisolone	NULL
differentially	NULL
regulates	NULL
IL-10	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
production	NULL
during	NULL
murine	NULL
endotoxemia	NULL
.	NULL

Clin	NULL
Exp	NULL
Immunol	NULL
.	NULL

106:91-96	NULL
.	NULL

Van	NULL
der	NULL
Poll	NULL
T	NULL
,	NULL
Barber	NULL
AFE	NULL
,	NULL
Coyle	NULL
SM	NULL
,	NULL
Lowry	NULL
SF	NULL
.	NULL

1996	NULL
Hypercortisolemia	NULL
increases	NULL
plasma	NULL
interleukin	NULL
10	NULL
concentrations	NULL
during	NULL
human	NULL
endotoxemia	NULL
.	NULL

A	NULL
clinical	NULL
research	NULL
center	NULL
study	NULL
.	NULL

J	NULL
Clin	NULL
Endocrinol	NULL
Metab	NULL
.	NULL

81:3604-3606	NULL
.	NULL

Platzer	NULL
C	NULL
,	NULL
Meisel	NULL
C	NULL
,	NULL
Vogt	NULL
K	NULL
,	NULL
Platzer	NULL
M	NULL
,	NULL
Volk	NULL
HD	NULL
.	NULL

1995	NULL
Up-regulation	NULL
of	NULL
monocytic	NULL
IL-10	NULL
by	NULL
tumor	NULL
necrosis	NULL
a	NULL
and	NULL
cAMP	NULL
elevating	NULL
drugs	NULL
.	NULL

Int	NULL
Immunol	NULL
.	NULL

7517-523	NULL
.	NULL

Kube	NULL
D	NULL
,	NULL
Platzer	NULL
C	NULL
,	NULL
von	NULL
Kneten	NULL
A	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
Isolation	NULL
of	NULL
the	NULL
human	NULL
interleukin-10	NULL
promoter	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
promoter	NULL
activity	NULL
in	NULL
Burkitt	NULL
's	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Cytokine	NULL
.	NULL

7:1-7	NULL
.	NULL

Collart	NULL
MA	NULL
,	NULL
Bauerle	NULL
P	NULL
,	NULL
Vassali	NULL
P.	NULL
1990	NULL
Regulation	NULL
of	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
transcription	NULL
in	NULL
macrophages	NULL
:	NULL
involvement	NULL
of	NULL
four	NULL
kappa	NULL
B-like	NULL
motifs	NULL
and	NULL
of	NULL
constitutive	NULL
and	NULL
inducible	NULL
forms	NULL
of	NULL
NF-kappa	NULL
B.	NULL
Mol	NULL
Cell	NULL
Biol	NULL
.	NULL

10:1498-1506	NULL
.	NULL

Imai	NULL
E	NULL
,	NULL
Miner	NULL
JN	NULL
,	NULL
Mitchell	NULL
JA	NULL
,	NULL
Yamamoto	NULL
KR	NULL
,	NULL
Granner	NULL
DK	NULL
.	NULL

1993	NULL
Glucocorticoid	NULL
receptor-cAMP	NULL
response	NULL
element-binding	NULL
protein	NULL
interaction	NULL
and	NULL
the	NULL
response	NULL
of	NULL
the	NULL
phosphoenolpyruvate	NULL
carboxykinase	NULL
gene	NULL
to	NULL
glucocorticoids	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

268:5353-5356	NULL
.	NULL

Arend	NULL
WP	NULL
.	NULL

1991	NULL
Interleukin	NULL
1	NULL
receptor	NULL
antagonist	NULL
:	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
interleukin	NULL
1	NULL
family	NULL
.	NULL

J	NULL
Clin	NULL
Invest	NULL
.	NULL

88:1445-1451	NULL
.	NULL

Artz	NULL
E	NULL
,	NULL
Sauer	NULL
J	NULL
,	NULL
Pollmacher	NULL
T	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1996	NULL
Glucocorticoids	NULL
suppress	NULL
interleukin-1	NULL
receptor	NULL
antagonist	NULL
synthesis	NULL
following	NULL
induction	NULL
by	NULL
endotoxin	NULL
.	NULL

Endo-crinology	NULL
.	NULL

134:672-677	NULL
.	NULL

Wang	NULL
Y	NULL
,	NULL
Zhang	NULL
JJ	NULL
,	NULL
Dai	NULL
W	NULL
,	NULL
Lei	NULL
KY	NULL
,	NULL
Pike	NULL
JW	NULL
.	NULL

1997	NULL
Dexamethasone	NULL
potently	NULL
enhances	NULL
phorbol	NULL
ester-induced	NULL
IL-1	NULL
beta	NULL
gene	NULL
expression	NULL
and	NULL
nuclear	NULL
factor	NULL
NF-kappaB	NULL
activation	NULL
.	NULL

J	NULL
Immunol	NULL
.	NULL

159:534-537	NULL
.	NULL

Berger	NULL
AF	NULL
,	NULL
Carter	NULL
DB	NULL
,	NULL
Hankey	NULL
SQ	NULL
,	NULL
McEwan	NULL
RN	NULL
.	NULL

1993	NULL
Cytokine	NULL
regulation	NULL
of	NULL
the	NULL
interleukin-1	NULL
receptor	NULL
antagonist	NULL
protein	NULL
in	NULL
U937	NULL
cells	NULL
.	NULL

Eur	NULL
J	NULL
Immunol	NULL
.	NULL

23:39-45	NULL
.	NULL

Auphan	NULL
N	NULL
,	NULL
Didonato	NULL
JA	NULL
,	NULL
Rosette	NULL
C	NULL
,	NULL
Helmberg	NULL
A	NULL
,	NULL
Karin	NULL
M.	NULL
1995	NULL
Immuno-suppression	NULL
by	NULL
glucocorticoids	NULL
:	NULL
inhibition	NULL
of	NULL
NF-kappaB	NULL
activity	NULL
through	NULL
induction	NULL
of	NULL
I	NULL
kappa	NULL
B	NULL
synthesis	NULL
.	NULL

Science	NULL
.	NULL

270:283-286	NULL
.	NULL

Vilcek	NULL
J	NULL
,	NULL
Lee	NULL
TH	NULL
.	NULL

1991	NULL
Tumor	NULL
necrosis	NULL
factor	NULL
.	NULL

New	NULL
insights	NULL
into	NULL
the	NULL
molecular	NULL
mechanisms	NULL
of	NULL
its	NULL
multiple	NULL
actions	NULL
.	NULL

J	NULL
Biol	NULL
Chem	NULL
.	NULL

266:7313-7316.	NULL
.	NULL

Wang	NULL
P	NULL
,	NULL
Wu	NULL
P	NULL
,	NULL
Siegel	NULL
MI	NULL
,	NULL
Egan	NULL
RW	NULL
,	NULL
Billah	NULL
MM	NULL
.	NULL

1995	NULL
Interleukin	NULL
10	NULL
inhibits	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
activation	NULL
in	NULL
human	NULL
monocytes	NULL
.	NULL
]	NULL

Biol	NULL
Chem	NULL
.	NULL

270:9558-9563	NULL
.	NULL

Van	NULL
Dullem	NULL
HM	NULL
,	NULL
Van	NULL
Deventer	NULL
SJ	NULL
,	NULL
Hommes	NULL
DW	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1995	NULL
Treatment	NULL
of	NULL
Crohn	NULL
's	NULL
disease	NULL
with	NULL
anti-tumor	NULL
necrosis	NULL
factor	NULL
chimeric	NULL
monoclonal	NULL
antibody	NULL
(	NULL
cA2	NULL
)	NULL
.	NULL

Gastroenterology	NULL
.	NULL

109:129-135	NULL
.	NULL

Van	NULL
Deventer	NULL
SJ	NULL
,	NULL
Elson	NULL
CO	NULL
,	NULL
Fedorak	NULL
RN	NULL
.	NULL

1997	NULL
Multiple	NULL
doses	NULL
of	NULL
intravenous	NULL
interleukin	NULL
10	NULL
in	NULL
steroid-refractory	NULL
Crohn	NULL
's	NULL
disease	NULL
.	NULL

Gastroenterology	NULL
.	NULL

113	NULL
:	NULL
383-389	NULL
.	NULL

